Saturday 17 October 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
690.00
6.49
−0.93%
Follow TMO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 5 | 8 |
+8 more TTM periods Free account |
| 13.51% | 13.52% | 13.02% | 13.14% | ||
| 6.50% | 6.45% | 6.46% | 6.46% | ||
ROIC |
5.80% | 5.56% | 6.12% | 5.92% | |
Return on Tangible Assets |
36.57% | 37.31% | 27.84% | 37.36% | |
Average Days of Receivables |
74.45 | 74.33 | 72.91 | 74.37 | |
Free Cash Flow per Share |
19.84 | 18.25 | 16.81 | 16.26 | |
Free Cash Flow |
7,362.00 | 6,789.00 | 6,337.00 | 6,145.00 | |
Capital Expenditures |
(1,651.00) | (1,498.00) | (1,481.00) | (1,506.00) | |
| Other line items | |||||
Cash ROIC |
7.67% | 7.13% | 6.38% | 7.11% | |
Accounts Receivable Turnover |
5.14 | 5.12 | 5.21 | 5.10 | |
Accounts Payable Turnover |
8.78 | 8.37 | 7.85 | 8.97 | |
Inventory Turnover |
4.90 | 4.99 | 5.06 | 4.60 | |
Average Days of Payables |
43.49 | 45.60 | 50.23 | 44.33 | |
Days of Inventory on Hand |
74.88 | 74.95 | 75.24 | 81.63 | |
Tax Rate |
(0.08) | (0.07) | (0.07) | (0.08) | |
Research and Development Expense of Revenue |
3.03% | 3.08% | 3.14% | 3.23% | |
Selling, General and Administrative Expense of Revenue |
19.48% | 19.55% | 19.60% | 19.62% | |
Share Based Compensation of Revenue |
0.69% | 0.70% | 0.70% | 0.70% | |
Interest Coverage |
5.55 | 5.37 | 5.46 | 5.48 | |
Operating CF/Net income |
1.29 | 1.21 | 1.17 | 1.16 | |
Depreciation/Fixed assets |
0.27 | 0.26 | 0.26 | 0.27 | |
Capex/Depreciation |
(0.56) | (0.53) | (0.53) | (0.54) | |
Revenue per Share |
124.89 | 121.50 | 118.19 | 115.70 | |
Operating CF per Share |
24.29 | 22.28 | 20.74 | 20.24 | |
Capex per Share |
(4.45) | (4.03) | (3.93) | (3.98) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 |
Columns are period end dates